Equities Analysts Set Expectations for SLN FY2027 Earnings

Silence Therapeutics plc (NASDAQ:SLN - Free Report) - Research analysts at William Blair increased their FY2027 EPS estimates for Silence Therapeutics in a report released on Thursday, May 8th. William Blair analyst M. Minter now expects that the company will post earnings of $13.66 per share for the year, up from their previous estimate of $13.57. The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics' FY2028 earnings at $24.35 EPS.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%.

Several other analysts have also commented on the stock. Morgan Stanley lowered their price objective on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. The Goldman Sachs Group reduced their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research note on Friday, May 9th. Chardan Capital reduced their target price on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, May 9th. BMO Capital Markets reduced their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Silence Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $33.83.

Silence Therapeutics Stock Performance

SLN stock traded down $0.05 during mid-day trading on Monday, hitting $4.06. The company had a trading volume of 196,576 shares, compared to its average volume of 299,307. The firm has a market cap of $121.52 million, a PE ratio of -2.59 and a beta of 1.20. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $24.38. The stock's fifty day moving average price is $3.36 and its two-hundred day moving average price is $6.30.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently bought and sold shares of the company. Walleye Capital LLC grew its stake in Silence Therapeutics by 274.1% during the first quarter. Walleye Capital LLC now owns 136,150 shares of the company's stock valued at $384,000 after acquiring an additional 99,753 shares in the last quarter. Jump Financial LLC purchased a new position in Silence Therapeutics during the first quarter valued at approximately $74,000. Woodline Partners LP grew its stake in Silence Therapeutics by 22.6% during the fourth quarter. Woodline Partners LP now owns 498,732 shares of the company's stock valued at $3,431,000 after acquiring an additional 91,829 shares in the last quarter. Two Sigma Advisers LP grew its stake in Silence Therapeutics by 18.6% during the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company's stock valued at $680,000 after acquiring an additional 15,500 shares in the last quarter. Finally, Redmile Group LLC lifted its position in Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock valued at $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.